VitalLife Scientific Wellness Center, a subsidiary of Bumrungrad International Hospital in Bangkok, Thailand and NEC Corporation, a leader in IT, network and AI technologies in Japan, have announced the introduction of NEC's FonesVisuas Test in Thailand. This innovative blood test, previously exclusive to Japan, now marks its international debut in the VitalLife Scientific Wellness Center.

According to the World Health Organization (WHO), the global rise in lifestyle-related diseases and dementia underscores the urgency for advanced predictive diagnostics. Concurrently, OECD iLibrary data has identified cancer and cardiovascular diseases as leading causes of mortality worldwide, amplifying the urgency for proactive health management solutions.

For over two decades, VitalLife has pioneered personalized healthcare solutions by integrating cutting-edge research and technology. The addition of the FonesVisuas Test represents a significant advancement by analyzing daily-changing proteins. From just a small blood sample, the test can predict risks associated with conditions such as dementia, heart attack, lung cancer, and chronic kidney disease over the next few years.

Going forward, NEC plans to expand provision of the FonesVisuas Test internationally, particularly in the APAC region, underscoring its commitment to advancing global healthcare standards.